Pressure BioSciences Converts Additional $7.24M of Debt into Equity: Total Conversions Exceed $13.6M in Past 30 Days Press Release | 06/12/2018
2015/2016 Debentures, Line-of-Credit, Promissory Note, & Misc. Short-Term Debt All Converted into Equity; Investors Signal Strong Support for Company's Planned 2018 Up-List
Mr. Joseph L. Damasio, VP of Finance and CFO of PBI, said, "With today's announced conversion of an additional $7.24M of debt to equity, total loan debt has been reduced from approximately $16.6M to approximately $3.0M, which is a level we believe the Company can manage. We are continuing to discuss the Company's progress with remaining debt holders, and anticipate that several more may follow the lead of the approximate 40+ investors who converted their debt into equity over the past 30 days. We believe such further conversions could reduce the amount of loan debt on our Balance Sheet by an additional 10-15%."
If you had the chance to Get Involved with a company, that is Believed to Be Years Ahead of Others with a Similar Type Instrument, Softwares, Technologies & Processes. A company that Currently Addresses Multi Billion $$ Markets-R&D, etc. Customer and potential customer base of, Top Universities, Labs, Big Pharma. With their current client base is excited, new customers anticipated, repeat sales to their base, new deals with new companies, universities, etc.
(PBIO)-Pressure BioSciences, Inc. Now has the Newest Generation of Technologies, Software & Processes. Unlike other similar companies, that has allowed them to Launch in to Additional-New Multi Billion $$$ Markets. Companies are contacting PBIO, great interest is being expressed in their newest instruments, software, technologies & processes. Theirs could be One of a Kind. Prior the Barocycler was mainly a R&D tool. Today it is so much more. Now, FDA, USDA, GMO, GMP compliant as well, the world is PBIO's Oyster so to speak.
A new technology - Ultra Shear Technology/Process will be Enabling CBD OILS to be MORE EFFECTIVE, it is anticipated, potentially lower dosages due to Better Absorption rates/percentages % in the body (as high as 80% v 10-20%), could also afford a cost savings not only for the manufacturer, but to the patient as well.
CLEAN LABEL FOODS-IMAGINE Milk-Toxin & Preservative Stripped-Bare Bones All NATURAL-NO Refrigeration Needed & Longer Shelf Life. The ability to mass produce or manufacture these items, on a Commercial Level, in the newest markets PBIO will segue into is going to create new revenues. Other markets applicable are Cosmetics, Paints, Oils & more.
Other new technologies come via the Barofold, Inc. acquisition (Technology-Process-All Patents & Intellectual Properties), which has already landed a New Contract with a Multi -Billion $ Pharma company. Two others at least have approached PBIO about contracts.
The other is the two - year agreement signed with ISS, Inc. bringing another cutting - edge instrument, technology and partner to PBIO.
These two new situations will create another division of PBIO. It puts PBIO in the Bio Pharma Drug Manufacturing space, business market. BioPharma, Biotherapeutical drugs & therapies, Nutraceuticals, etc., That could lead to the Possibility of a New Drug, Making it To Market when it would have failed FDA clearance in the past. The possibility of Safer, more effective drugs, and the potential For Royalties if new drugs are created, are approved, hitting the market.
Would You Consider That/This Company, the huge future upside, even though the volume has been historically low? Would you take the opportunity when quiet, before the company evolves into one of the best in the markets they are serving, gains a larger following and support base and wait? Hold for the long play.
Pressure BioSciences, Inc. (OTCQB:PBIO) is That Company. Already with an impressive Client List of over 180, over 300 placements of their instruments worlwide. Three new instruments due out by year end 2018. Further Domestic and International expansion (China Center of Excellence is operational now). A larger than ever Sales Staff, fully trained and ready to hit the streets. Nine Consecutive Quarters of Growth-Increases in sales and revenues. Moving closer to a profitable status, and an up listing.
With a very thin, Low Float and support-volume, can move quickly back to $5.00 and higher. We believe PBIO is a Long Play, with possible short-term gain potential. You must admit, the brightest of futures in on the not too distant horizon. PBIO looks to become a major international player, sooner than later. What more could one ask for in a company? Do yourself a favor. Do your research, due diligence, the only thing lacking is steady volume. PBIO is rapidly Morphing.
Robert E. Kreh – Principal
Small Cap Solutions, LLC
You are receiving this because you have requested the information contained in this email, and/or have expressed an interest recently, or in the past to be included in such emails. And/or have requested information/news/updates for Pressure BioSciences, Inc. This profile has been compiled by Small Cap Solutions, LLC based on information from the company believed to be true/factual. This profile is not guaranteed, neither implied, nor in writing, as to the accuracy and completeness of content, and prepared for information purposes only. As such, this profile may contain forward reaching statements, as defined in the Private Securities Litigation Act of 1995. Actual results could differ materially from the statements either expressed or implied herein. Prospective investors are advised to review the Company's periodic filings with the Securities and Exchange Commission or at otcmarkrts.com yahoofinance.com - Small Cap Solutions, LLC has received ($3,000.00) cash from Value Quest, Inc. for investor relations services rendered for Pressure BioSciences, Inc. Additional inquiries are available by email to or in writing to Small Cap Solutions, LLC 303 Joppa Crossing Ct (Suite #1) Joppa, Md. 21085 This is not a solicitation to buy or sell securities. To "unsubscribe to this mailing list, please reply "unsubscribe" to this message.
Disclaimer: All Micro/Small Cap Company(ies) profile(s) are/have been compiled by Small Cap Solutions, LLC based on information believed to be true and gathered either from client companies and/or third party('s)/web sites. These profiles are not guaranteed, neither implied, nor in writing, as to the accuracy and completeness of content, and has been prepared for information purposes only. As such, this profile may contain forward reaching statements, as defined in the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from the statements either expressed or implied herein. Prospective investors are advised to review the Company's periodic filings with the Securities and Exchange Commission or at and/or Small Cap Solutions, LLC may receive cash or stock from client companies for investor relations services rendered.
Small Cap Solutions, LLC and/or its Principal/Employees are not registered Broker(s)/Broker Dealer(s) with FINRA or the SEC. Small Cap Solutions, LLC does not make any buy/sell recommendations at any time, but may state their opinion on companies, etc. That is not meant to be a recommendation. All information disseminated by Small Cap Solutions, LLC is believed to be true and public. Additional inquiries available by email to or by mail to 303 Joppa Crossing Ct. (Suite#1) Joppa, Md. 21085. To unsubscribe to this mailing list, please reply "unsubscribe" to this message or by mail to 303 Joppa Crossing Ct. (Suite#1) Joppa, Md. 21085. To unsubscribe to this mailing list, please reply "unsubscribe" to this message.
Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.